Keywords
Last Name
Institution

Janice L. Gabrilove

TitlePROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
AddressRuttenberg Treatment Center
New York NY 10029
Phone212-241-9650
Fax212-289-0678
    Other Positions
    TitlePROFESSOR
    InstitutionMount Sinai
    DepartmentOncological Sciences


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Arita A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Gabrilove J, Brody JD. Signaling pathways in lymphoma: pathogenesis and therapeutic targets. Future Oncol. 2013 Oct; 9(10):1549-71.
      View in: PubMed
    2. Solan S, Wallenstein S, Shapiro M, Teitelbaum SL, Stevenson L, Kochman A, Kaplan J, Dellenbaugh C, Kahn A, Biro FN, Crane M, Crowley L, Gabrilove J, Gonsalves L, Harrison D, Herbert R, Luft B, Markowitz SB, Moline J, Niu X, Sacks H, Shukla G, Udasin I, Lucchini RG, Boffetta P, Landrigan PJ. Cancer incidence in world trade center rescue and recovery workers, 2001-2008. Environ Health Perspect. 2013 Jun; 121(6):699-704.
      View in: PubMed
    3. Messer CK, Fowkes ME, Gabrilove JL, Post KD, Son H, Levine AC. ACTH-producing remnants following apoplexy of an ACTH-secreting pituitary macroadenoma. Pituitary. 2012 Dec; 15 Suppl 1:S6-9.
      View in: PubMed
    4. Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, Jing Y. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res. 2012 Dec 15; 18(24):6690-701.
      View in: PubMed
    5. Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma. 2012 Mar; 53(3):435-40.
      View in: PubMed
    6. Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, Sparano JA. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011 Jan 15; 117(2):336-42.
      View in: PubMed
    7. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010 Oct 28; 116(17):3163-70.
      View in: PubMed
    8. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010 Feb 1; 28(4):549-55.
      View in: PubMed
    9. Gabrilove JL. The polycystic ovary unraveled. Endocr Pract. 2009 May-Jun; 15(4):386.
      View in: PubMed
    10. Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008 Jul; 142(3):379-93.
      View in: PubMed
    11. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer. 2007 Oct 1; 110(7):1629-40.
      View in: PubMed
    12. Messer CK, Kirschenbaum A, New MI, Unger P, Gabrilove JL, Levine AC. Concomitant secretion of glucocorticoid, androgens, and mineralocorticoid by an adrenocortical carcinoma: case report and review of literature. Endocr Pract. 2007 Jul-Aug; 13(4):408-12.
      View in: PubMed
    13. Leibowitz AB, Adamsky C, Gabrilove J, Labow DM. Intraoperative acute tumor lysis syndrome during laparoscopic splenectomy preceded by splenic artery embolization. Surg Laparosc Endosc Percutan Tech. 2007 Jun; 17(3):210-1.
      View in: PubMed
    14. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7; 355(23):2408-17.
      View in: PubMed
    15. Gabrilove J. Granulocyte colony stimulating factor for mucositis during post-operative radiotherapy. Cancer J. 2006 May-Jun; 12(3):167-9.
      View in: PubMed
    16. Gabrilove JL. An analysis of current neutropenia therapies, including pegfilgrastim. Clin Cornerstone. 2006; 8 Suppl 5:S19-28.
      View in: PubMed
    17. Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005 Nov; 29(11):1253-7.
      View in: PubMed
    18. Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, Larson RA. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005 Jun 1; 11(11):4176-81.
      View in: PubMed
    19. Gabrilove J. Anemia and the elderly: clinical considerations. Best Pract Res Clin Haematol. 2005; 18(3):417-22.
      View in: PubMed
    20. Gabrilove JL, Sarokhan B, Cremieux P. Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy. J Clin Oncol. 2002 Jun 1; 20(11):2757-8.
      View in: PubMed
    21. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002 Apr; 3(1):45-51.
      View in: PubMed
    22. Gabrilove JL. The pathogenesis of the polycystic ovary syndrome: a hypothesis. Endocr Pract. 2002 Mar-Apr; 8(2):127-32.
      View in: PubMed
    23. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002 Feb; 3(3):180-90.
      View in: PubMed
    24. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001 Jun 1; 19(11):2875-82.
      View in: PubMed
    25. Gabrilove JL. Hematologic malignancies: an opportunity for targeted drug therapy. Oncologist. 2001; 6 Suppl 5:1-3.
      View in: PubMed
    26. Gabrilove JL. Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies. Oncologist. 2001; 6 Suppl 5:4-7.
      View in: PubMed
    Gabrilove's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067